Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Moderna Rises As Vaccine Makers Assess New Variant

Published 29/11/2021, 21:50
Updated 29/11/2021, 21:50
©  Reuters

© Reuters

By Sam Boughedda

Investing.com — Moderna Inc (NASDAQ:MRNA) shares have rallied Monday after the emergence of the new Covid-19 variant, Omicron, which has vaccine makers examining whether a new booster shot will need to be produced. 

Moderna shares are trading around 11.3% above Friday's close.

Moderna's CEO, Stephane Bancel, told CNBC that it will take months to develop a booster shot explicitly designed for the new variant, but a higher dose of its current shot could be ready much sooner.

However, he also acknowledged that the variant is likely to be in most countries already. On Sunday, Moderna's Chief Medical Officer Paul Burton said he suspects the new variant may elude current vaccines, but they will know more in the next couple of weeks. 

"We should know about the ability of the current vaccine to provide protection in the next couple of weeks," said Burton, speaking on the BBC's Andrew Marr Show. “If we have to make a brand new vaccine, I think that’s going to be early 2022,” he added.

Initial comments from a South African doctor who was one of the first to raise the alarm about the strain said the symptoms were so far very mild and could be treated at home. If that is the same for most cases — which may be true if it is already prevalent globally — a specifically designed booster shot may not be warranted. 

In a research note over the weekend, Piper Sandler analyst Edward Tethoff reiterated his Overweight rating at $348 price target on Moderna, saying the company is in a better position to develop another vaccine and has the capacity to manufacture several hundred million doses every month.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.